clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with clarithromycin
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Wang G et al. | Multiplex sequence analysis demonstrates the competitive growth advantage of the A-to-G mutants of clarithromycin-resistant Helicobacter pylori. | 1999 | Antimicrob. Agents Chemother. | pmid:10049289 |
Goto T et al. | [Erosive duodenitis after eradication therapy for Helicobacter pylori]. | 1999 | Nihon Shokakibyo Gakkai Zasshi | pmid:10047687 |
Kihira K et al. | [Triple therapy regimens involving H2 blockaders for therapy of Helicobacter pylori infections]. | 1999 | Nippon Rinsho | pmid:10036953 |
Nakagawa M et al. | [A comparative study; one week treatment versus two weeks treatment with lansoprazol, amoxycillin and clarythromycin for the eradication of Helicobacter pylori in patient with gastric and duodenal ulcer]. | 1999 | Nippon Rinsho | pmid:10036952 |
Shirai T et al. | [Four kinds of new triple therapy regiments for Helicobacter pylori eradication in patients with peptic ulcer]. | 1999 | Nippon Rinsho | pmid:10036951 |
Habu Y et al. | [Evaluation of the efficacy and the cost-effectiveness of proton pump inhibitor-based dual and triple therapy regimens for H. pylori eradication in peptic ulcer disease]. | 1999 | Nippon Rinsho | pmid:10036950 |
Iwasaki A | [Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy]. | 1999 | Nippon Rinsho | pmid:10036949 |
Sekine H et al. | [Recurrence rate of H. pylori after successful eradication and second eradication therapy after initial failure of treatment]. | 1999 | Nippon Rinsho | pmid:10036947 |
Maeda S and Yoshida H | [Detection of Helicobacter pylori 23S rRNA gene mutation associated with clarithromycin resistance and its clinical applicability]. | 1999 | Nippon Rinsho | pmid:10036941 |
Murakami K and Kimoto M | [Antibiotic-resistant H. pylori strains in the last ten years in Japan]. | 1999 | Nippon Rinsho | pmid:10036940 |
Fukazawa K et al. | [Antimicrobial resistance testing of H. pylori epsilometer test and disk diffusion test]. | 1999 | Nippon Rinsho | pmid:10036939 |
Sakurai K et al. | [Importance of drug selection and the use of sensitivity tests for the eradication therapy for Helicobacter pylori]. | 1999 | Nippon Rinsho | pmid:10036938 |
Horgen L et al. | Postantibiotic effects of rifampin, amikacin, clarithromycin and ethambutol used alone or in various two-, three- and four-drug combinations against Mycobacterium avium. | 1999 | FEMS Immunol. Med. Microbiol. | pmid:10030545 |
Goh KL et al. | Optimal treatment for duodenal ulcer disease: a cost-decision analysis in Malaysian patients. | 1999 | J. Gastroenterol. Hepatol. | pmid:10029275 |
Dubé MP et al. | Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group. | 1999 | Clin. Infect. Dis. | pmid:10028084 |
pmid: |